Article
Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
Viruses - 4 Mar 2024
Chu Carolyn, Tao Kaiming, Kouamou Vinie, Avalos Ava, Scott Jake, Grant Philip M, Rhee Soo-Yon, McCluskey Suzanne M, Jordan Michael R, Morgan Rebecca L, Shafer Robert W
Abstract excerpt
BACKGROUND: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART. METHODS: We performed a PubMed search using the term "Dolutegravir", last updated 18...
Topics
Join the communities discussing this publication.
